Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
natural source : Www.biospace.com save search
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Published: 2024-04-03 (Crawled : 19:00) - biospace.com/
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: -0.59%
H: 2.09%
C: -1.74%
rna-3927 mrna therapy
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
DYAI A | $1.61 1.26% 1.24% 14K
|
Health Technology
|
| O: 0.48%
H: 0.87%
C: -4.12%
primate antibody publication communications study
Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients
Published: 2024-03-04 (Crawled : 16:00) - biospace.com/
TSOI | $0.0007 0.0% 33M
|
Manufacturing
|
| O: 10.0%
H: 18.18%
C: 9.09%
covid-19 quadramune patent natural granted international cell solutions
MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer
Published: 2024-02-07 (Crawled : 00:00) - biospace.com/
MAIA | $2.15 9.69% 0.0% 100K
|
|
| O: 0.0%
H: 0.0%
C: -3.4%
lung positive cancer publication cell treatment communications potential
Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
Published: 2024-01-25 (Crawled : 13:00) - biospace.com/
NTRA S | $85.275 -2.3% -2.35% 2.5M
|
Health Services
|
| O: 0.59%
H: 0.64%
C: -2.09%
gastrointestinal
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
Published: 2023-12-19 (Crawled : 08:00) - biospace.com/
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 0.91%
H: 0.72%
C: 0.11%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: 0.0%
IPHA | $2.48 5.53% 5.24% 9.4K
|
Health Technology
|
| O: 13.88%
H: 0.0%
C: -3.58%
pharma natural cell sanofi
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
Published: 2023-12-04 (Crawled : 13:30) - biospace.com/
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: 3.81%
H: 3.85%
C: 1.93%
arcus publication treatment
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
Published: 2023-11-02 (Crawled : 15:00) - biospace.com/
RLYB | News | $1.75 4.79% 4.57% 310K
|
|
| O: 0.0%
H: 5.2%
C: -2.84%
natural presentation meeting study
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis
Published: 2023-10-17 (Crawled : 00:00) - biospace.com/
NKTX | $7.26 -6.8% -7.3% 730K
|
Health Technology
|
| O: -0.68%
H: 168.71%
C: 113.61%
partnership lupus natural cell therapeutics therapy
Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201
Published: 2023-10-16 (Crawled : 23:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
gda-201 candidate natural cell therapy study
FDA Selects Ontada to Investigate the Natural History of Rare Cancers Treated in the U.S. Community Oncology Setting
Published: 2023-10-11 (Crawled : 15:00) - biospace.com/
MCK | $524.83 1.16% -0.05% 650K
|
Distribution Services
|
| O: -0.18%
H: 0.86%
C: 0.65%
fda rare natural
Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BOTOX® Cosmetic)
Published: 2023-08-30 (Crawled : 15:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
botox treatment
Exploring the Impact of Natural Disasters After Pfizer Plant Damaged
Published: 2023-07-24 (Crawled : 12:20) - biospace.com/
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: 0.0%
H: 1.48%
C: 0.7%
natural impact
CAR T-Cell Study Enabled by 10x Genomics Single Cell Technology Published in Nature Medicine
Published: 2023-07-06 (Crawled : 06:00) - biospace.com/
TXG | $27.92 -3.56% -3.69% 2M
|
Health Technology
|
| O: -2.0%
H: 1.42%
C: 0.28%
t-cell genomics cell technology study
Study Published in Nature Medicine Highlights use of Vizgen MERSCOPE® Platform for Understanding Effects of Neoadjuvant Immunotherapy for Patients with Hepatocellular Carcinoma (HCC)
Published: 2023-06-20 (Crawled : 12:00) - biospace.com/
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.52%
H: 1.08%
C: 0.29%
merscope immunotherapy study platform
Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome
Published: 2023-06-08 (Crawled : 17:00) - biospace.com/
ACAD | $16.82 -1.47% -1.49% 3.5M
|
Health Technology
|
| O: -1.1%
H: 4.89%
C: 3.0%
results study rett syndrome
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
Published: 2023-06-06 (Crawled : 12:00) - biospace.com/
RPTX 4 | $3.14 3.97% 3.82% 220K
|
Health Technology
|
| O: 0.94%
H: 3.71%
C: -1.77%
tumors publication therapeutics
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology
Published: 2023-04-26 (Crawled : 12:00) - biospace.com/
ATHE | $2.04 -4.67% -4.9% 54K
|
Health Technology
|
| O: -0.14%
H: 0.35%
C: -1.07%
natural sensor therapeutics study
Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses
Published: 2023-04-13 (Crawled : 15:00) - biospace.com/
SANA | $7.605 -1.62% -1.64% 3.4M
|
|
| O: 1.87%
H: 29.97%
C: 28.27%
cd19 preclinical communications
New Study Findings Published in Nature Show Circulating Tumor DNA (ctDNA) Can Predict and Detect Cancer Recurrence Earlier In Non-Small Cell Lung Cancer
Published: 2023-04-13 (Crawled : 14:00) - biospace.com/
NVTA | $0.019 0.0% 22M
|
Health Services
|
| O: 3.05%
H: 9.63%
C: 5.93%
lung cancer cell tumor dna show study
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
PZG | $0.4431 0.48% 2.91% 150K
|
Non-Energy Minerals
SIX | $23.45 -0.55% 0.68% 650K
|
Consumer Services
KNSL 4 | $451.81 -0.02% 0.49% 140K
|
Finance
SENS | $0.3992 -4.04% 0.45% 2M
|
Electronic Technology
LAD | $261.0 0.25% 0.4% 230K
|
Retail Trade
Your saved searches
Save your searches and get alerts when important news are released.